SARS-CoV-2 B.1.351 spike exhibits the superior immunogenicity among multiple variants

Figure S1. Heat map of IgG binding antibodies induced by Ad5-B.1.1.7, Ad5-B.1.351, Ad5-P.1, Ad5-B.1.429 and Ad5-WT in mice. BALB/c mice (n = 10 per group) received a single intramuscular immunization with Ad5-B.1.1.7, Ad5-B.1.351, Ad5-P.1, Ad5-B.1.429, Ad5-WT or Ad5-null at day 0. Sera were collected at 4 weeks after immunization, and IgG binding antibodies against spike, RBD, NTD of B.1.1.7, P.1.351, P.1 variants and the wild-type strain were detected using ELISA method. The data in the Ad5-null control group were not shown because all of them were sero-negative. Figure S2. Heat map of pseudovirus neutralizing antibodies induced by Ad5-B.1.1.7, Ad5-B.1.351, Ad5-P.1, Ad5-B.1.429 and Ad5-WT in mice. BALB/c mice (n = 10 per group) received a single intramuscular immunization with Ad5-B.1.1.7, Ad5-B.1.351, Ad5-P.1, Ad5-B.1.429, Ad5-WT or Ad5-null at day 0. Sera were collected at 4 weeks after immunization. Neutralization assays were performed using HIV backbone-derived pseudovirus bearing spikes of the wild-type strain and B.1.1.7, B.1.351, P.1, B.1.429 and B.1.617 variants using microneutralization assay based on luciferase reporter gene. The data in the Ad5-null control group were not shown because all of them were sero-negative. The PNAb GMT was standardized and transfromed to ratio compared to the highest GMT value of the vaccine group in each pseudovirus NAb test. Table S1. IgG GMT against spike, RBD and NTD of variants and wild-type strain induced by Ad5-B.1.1.7, Ad5-B.1.351, Ad5-P.1, Ad5-B.1.429, Ad5-WT or Ad5-null. Table S2. NAb GMT against HIV-derived pseudovirus bearing spikes of variants and wild-type strain induced by Ad5-B.1.1.7, Ad5-B.1.351, Ad5-P.1, Ad5-B.1.429, Ad5-WT or Ad5-null.图S1. Ad5-B.1.1.7、Ad5-B.1.351、Ad5-P.1、Ad5-B.1.429与Ad5-WT免疫小鼠后诱导产生的IgG结合抗体热图。BALB/c小鼠（每组n=10）于第0天单次肌内免疫Ad5-B.1.1.7、Ad5-B.1.351、Ad5-P.1、Ad5-B.1.429、Ad5-WT或Ad5-null。免疫后4周采集血清，采用酶联免疫吸附试验（ELISA）检测针对B.1.1.7、P.1.351、P.1变体及野生型毒株的刺突蛋白（spike）、受体结合域（RBD）、N端结构域（NTD）的IgG结合抗体。Ad5-null对照组数据因全部血清呈阴性而未展示。 图S2. Ad5-B.1.1.7、Ad5-B.1.351、Ad5-P.1、Ad5-B.1.429与Ad5-WT免疫小鼠后诱导产生的假病毒中和抗体热图。BALB/c小鼠（每组n=10）于第0天单次肌内免疫Ad5-B.1.1.7、Ad5-B.1.351、Ad5-P.1、Ad5-B.1.429、Ad5-WT或Ad5-null。免疫后4周采集血清，采用基于荧光素酶报告基因的微量中和试验，使用携带野生型毒株及B.1.1.7、B.1.351、P.1、B.1.429、B.1.617变体刺突蛋白（spike）的HIV骨架假病毒开展中和实验。Ad5-null对照组数据因全部血清呈阴性而未展示。本试验中，假病毒中和抗体（PNAb）的几何平均滴度（GMT）经标准化处理后，以各假病毒中和试验中疫苗组最高GMT值为参照转换为比值。 表S1. Ad5-B.1.1.7、Ad5-B.1.351、Ad5-P.1、Ad5-B.1.429、Ad5-WT或Ad5-null免疫后，针对各变体及野生型毒株刺突蛋白（spike）、受体结合域（RBD）、N端结构域（NTD）的IgG几何平均滴度（GMT）。 表S2. Ad5-B.1.1.7、Ad5-B.1.351、Ad5-P.1、Ad5-B.1.429、Ad5-WT或Ad5-null免疫后，针对携带各变体及野生型毒株刺突蛋白（spike）的HIV来源假病毒的中和抗体几何平均滴度（GMT）。